Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05593055 · ClinicalTrials.gov registry record · Phase 4

Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension

A Phase 4 study of Hypertension and Left Ventricular Hypertrophy, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 4
Development phase
75
Enrollment target
1
Study location

NCT05593055: Recruiting Phase 4 study of Hypertension and Left Ventricular Hypertrophy, sponsored by Brigham and Women's Hospital.

NCT05593055 is a Phase 4 study of Hypertension and Left Ventricular Hypertrophy that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 75 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05593055, a Phase 4 study of Hypertension and Left Ventricular Hypertrophy, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 4
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with improvements in LV structure and function. The investigators will achieve this through a randomized, controlled, basic experimental study involving humans (BESH).

Primary Outcome

Change in myocardial flow reserve (ratio of hyperemic stress myocardial blood flow to rest myocardial blood flow)

Interventions

  • DRUG Chlorthalidone
  • DRUG Eplerenone
  • DRUG Potassium

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2023-08-25
Est. Completion 2027-12-31
Phase Phase 4
Brigham and Women's Hospital

937 total trials

What NCT05593055 shows while recruiting

NCT05593055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower).

The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Chlorthalidone is the first listed.

NCT05593055 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05593055 about?

NCT05593055 is a clinical study titled "Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension". The investigators' goal is to show that in hypertensive men and women with left ventricular hypertrophy (LVH) treatment with a mineralocorticoid receptor (MR) antagonist, versus a thiazide-like diuretic, will improve coronary microvascular function and cardiac efficiency, which will associate with i...

What is the current status of trial NCT05593055?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2023-08-25. Estimated completion is 2027-12-31.

What conditions does trial NCT05593055 study?

This clinical trial studies the following conditions: Hypertension, Left Ventricular Hypertrophy.

What interventions are being tested in trial NCT05593055?

The interventions under investigation include: Chlorthalidone (DRUG), Eplerenone (DRUG), Potassium (DRUG).

Who is sponsoring clinical trial NCT05593055?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05593055 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05593055's enrollment target sits among peer trials

75 323rd of 470 higher than 142 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05593055, the US trial registry maintained by the National Library of Medicine. NCT05593055 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.